Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

• Published in: The oncologist (Dayton, Ohio) Vol. 25; no. 3; pp. e536 - e544
• Main Authors: Aso, Mari, Toi, Yukihiro, Sugisaka, Jun, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Ogasawara, Takahiro, Tsurumi, Kyoji, Ono, Kana, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Kawashima, Yosuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.03.2020
• Subjects: Lung Cancer; Rheumatoid factor; Immune-related adverse events; Skin reaction; Immunotherapy; Lung cancer; Programmed cell death 1

Anti-programmed cell death 1 antibody is a standard therapy for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs), such as skin reactions, are frequently observed. Although skin reactions are associated with clinical efficacy in melanoma, this association in...